DEA Blocks Public Access to Cannabis Rescheduling Hearing
Administrative law judge denies livestreaming for pivotal cannabis rescheduling hearing featuring only reform opponents, raising transparency concerns.
The Drug Enforcement Administration faces mounting pressure to open its cannabis rescheduling hearing to public scrutiny after Chief Administrative Law Judge Derek Julis denied requests for livestreaming access. The hearing, set to begin next week, represents a critical juncture for the industry as federal regulators weigh moving cannabis from Schedule I to Schedule III under the Controlled Substances Act.
The closed-door format raises immediate concerns about procedural fairness, particularly given that invited participants reportedly consist exclusively of rescheduling opponents. This participant selection suggests the hearing may focus heavily on maintaining current restrictions rather than examining the full spectrum of evidence supporting rescheduling. Cannabis companies have waited months for clarity on the rescheduling timeline, with many operators banking their expansion strategies on federal reform.
The lack of transparency compounds existing uncertainty that has weighed on cannabis equity valuations throughout 2024. Multi-state operators like Curaleaf (OTCQX: CURLF) and Green Thumb Industries (OTCQX: GTBIF) have seen their stock prices fluctuate significantly based on rescheduling speculation, with investors parsing every regulatory development for signals about federal policy direction. The closed hearing format provides no mechanism for real-time market assessment of testimony or evidence presented.
Rescheduling to Schedule III would eliminate the 280E tax burden that currently prevents cannabis companies from deducting standard business expenses, potentially improving margins by 15-30% for profitable operators. However, the hearing's apparent focus on opposition voices suggests regulators may be building a record to support maintaining current scheduling or implementing a more limited reform package.
The transparency dispute highlights broader tensions between federal agencies and an industry seeking legitimacy through regulatory normalization. Without public access to the hearing proceedings, investors and operators must rely on secondhand accounts and regulatory tea-leaf reading to gauge the likelihood of meaningful reform. This information asymmetry perpetuates the regulatory uncertainty that has kept institutional capital largely sidelined from cannabis investments, limiting sector growth and professional market development.